rtx board of directors declares quarterly cash dividend
ARLINGTON, Va., Oct. 9, 2024 /PRNewswire/ — RTX (NYSE: RTX) announced today that its Board of Directors declared a dividend of 63 cents per outstanding share of RTX common stock. The dividend will be payable on Dec. 12, 2024 to shareowners of record at the close of business on Nov. 15, 2024.
RTX has paid cash dividends on its common stock every year since 1936.
About RTX
With more than 185,000 global employees, RTX pushes the limits of technology and science to redefine how we connect and protect our world. Through industry-leading businesses – Collins Aerospace, Pratt & Whitney, and Raytheon – we are advancing aviation, engineering integrated defense systems, and developing next-generation technology solutions and manufacturing to help global customers address their most critical challenges. The company, with 2023 sales of $69 billion, is headquartered in Arlington, Virginia.
Cautionary Statement Regarding Forward-Looking Statements
This release includes statements related to dividends that constitute “forward-looking statements” under the securities laws. All forward-looking statements involve risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Past dividends provide no assurance as to future dividends. The timing, payment and amount of future dividends, if any, could vary significantly from past dividends due to a number of risks and uncertainties. These factors include those described under the caption “Risk Factors” in our reports on Forms 10-K, 10-Q and 8-K filed with the SEC from time to time.
Media Contact
C: 202.384.2474
Investor Contact
C: 781.522.5123
SOURCE RTX
WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

Newsrooms &
Influencers

Digital Media
Outlets

Journalists
Opted In
Related news for (RTX)
- Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
- Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
- Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
- Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
- Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025